Get started
Author

Kathelijne C.J.M. Kraal

Observed names: K. C.J.M. Kraal, K.C.J.M. Kraal, Kathelijne C. J. Kraal, Kathelijne C. J. M. Kraal, Kathelijne C. Kraal, Kathelijne CJM Kraal, Kathelijne Kraal, Kraal, Kathelijne, Kraal, Kathelijne C.J., Kraal, Kathelijne Cjm
Observed institutions: University of Geneva, Leiden University, Utrecht University, Leiden University Medical Center, Amsterdam UMC Location University of Amsterdam, Emma Kinderziekenhuis, University Hospital of Geneva, Universitätsmedizin Göttingen, Princess Máxima Center
ORCID: 0000-0001-9630-0814
Observed ORCID: 0000-0001-9630-0814
OpenAlex ID: A5057437631
Neuroblastoma between 1990 and 2014 in the Netherlands: Increased incidence and improved survival of high-risk neuroblastoma
2019 · M.L. Tas, A.M.J. Reedijk, et al. · European Journal of Cancer · 78
PDF
A joint international consensus statement for measuring quality of survival for patients with childhood cancer
2023 · Rebecca J. van Kalsbeek, Melissa M. Hudson, et al. · Nature Medicine · 49
PDF
Upfront treatment of high‐risk neuroblastoma with a combination of 131I‐MIBG and topotecan
2015 · Kathelijne C.J.M. Kraal, Godelieve A.M. Tytgat, et al. · Pediatric Blood & Cancer · 40
PDF
Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
2021 · Thomas Blom, Roosmarijn Lurvink, et al. · Frontiers in Oncology · 32
PDF
Treatment and outcome of neuroblastoma with intraspinal extension: A systematic review
2017 · Kathelijne Kraal, Thomas Blom, et al. · Pediatric Blood & Cancer · 32
PDF
Neuroblastoma stage 4S: Tumor regression rate and risk factors of progressive disease
2019 · Michelle L. Tas, Michelle Nagtegaal, et al. · Pediatric Blood & Cancer · 31
PDF
Role of NKG2D, DNAM-1 and natural cytotoxicity receptors in cytotoxicity toward rhabdomyosarcoma cell lines mediated by resting and IL-15-activated human natural killer cells
2015 · Gerharda H. Boerman, Monique M. van Ostaijen-ten Dam, et al. · Cancer Immunology Immunotherapy · 31
PDF
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war
2022 · Asya Agulnik, Roman Kizyma, et al. · The Lancet Haematology · 26
Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma
2017 · Kathelijne CJM Kraal, Elvira C van Dalen, et al. · Cochrane Database of Systematic Reviews · 22
PDF
Neuroblastoma With Intraspinal Extension: Health Problems in Long‐Term Survivors
2016 · Kathelijne Kraal, Thomas Blom, et al. · Pediatric Blood & Cancer · 22
Spinal Canal Involvement in Neuroblastoma
2017 · Toby Trahair, Stefania Sorrentino, et al. · The Journal of Pediatrics · 19
Development of a centralised triage centre for children with cancer and blood disorders in response to the humanitarian crisis in Ukraine
2023 · Marta Salek, Alexandra Mueller, et al. · The Lancet Oncology · 16
Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma
2021 · Celina L. Szanto, Annelisa M. Cornel, et al. · Cancers · 14
PDF
Peripheral Stem Cell Apheresis is Feasible Post 131Iodine-Metaiodobenzylguanidine-Therapy in High-Risk Neuroblastoma, but Results in Delayed Platelet Reconstitution
2018 · Kathelijne C.J.M. Kraal, Ilse Timmerman, et al. · Clinical Cancer Research · 10
PDF
Optic nerve relapse in a child with common acute lymphoblastic leukemia, treated with systemic anti-CD-20 (rituximab).
2005 · Kathelijne Kraal, Nicoline Schalij-Delfos, et al. · PubMed · 10
Global consensus from the PHITT consortium surrounding an interim chemotherapy guidance for the treatment of children with hepatoblastoma, hepatocellular neoplasm – not otherwise specified (HCN-NOS), hepatocellular carcinoma and fibrolamellar carcinoma after trial closure
2025 · Irene Schmid, Allison F. O’Neill, et al. · EJC Paediatric Oncology · 9
PDF
A narrative review of 35 years of meta-[131I]iodobenzylguanidine therapy in neuroblastoma
2024 · Atia Samim, Gitta Bleeker, et al. · EJC Paediatric Oncology · 8
PDF
Cisplatin and carboplatin pharmacokinetics in a pediatric patient with hepatoblastoma receiving peritoneal dialysis
2020 · A. Laura Nijstad, Natasha K. A. van Eijkelenburg, et al. · Cancer Chemotherapy and Pharmacology · 6
PDF
High-plex imaging of hepatoblastoma and adjacent liver in pediatric patients reveals a predominant myeloid infiltrate expressing immune-checkpoints
2025 · Daniëlle Krijgsman, Stephanie A. Schubert, et al. · Cancer Immunology Immunotherapy · 5
Examining the Potential Relationship Between Multidisciplinary Team Meetings and Patient Survival in Pediatric Oncology Settings: A Systematic Review
2020 · Suzan Dijkstra, Kathelijne C.J.M. Kraal, et al. · Journal of Pediatric Hematology/Oncology · 5
Locoregional control in high-risk neuroblastoma using highly-conformal image-guided radiotherapy, with reduced margins and a boost dose for residual lesions
2024 · Atia Samim, Annemieke S. Littooij, et al. · Radiotherapy and Oncology · 4
PDF
Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis
2021 · Michelle L. Tas, Lisa W. Dootjes, et al. · Cancers · 4
PDF
Spinal Canal Involvement in Peripheral Neuroblastic Tumors
2019 · Shifra Ash, Stefania Sorrentino, et al. · Springer eBooks · 4
Effect of MYCN Amplification on Tumor Response and Recurrence in Patients With Stage IV Neuroblastoma
2026 · Yvette A. H. Matser, André B. P. van Kuilenburg, et al. · JCO Precision Oncology · 3
PDF
PEGylated Granulocyte Colony-Stimulating Factor and Plerixafor Enhance Autologous Stem and Progenitor Cell Mobilization and Transplantation in Pediatric Patients
2025 · Caroline Hochheuser, Maria L. Rozeman, et al. · Stem Cells and Development · 3
PDF
Works count: 50
Citation count: 496
H-index: 13
I10-index: 15
Year
Topic
Type